Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome.
Beth M DeJonghPublished in: The mental health clinician (2021)
Antipsychotic medications increase the risk of metabolic syndrome, which then increases the risk of atherosclerotic cardiovascular disease and premature death. Routinely monitoring for signs of metabolic syndrome in patients taking antipsychotics allows for early detection and intervention. Psychiatric pharmacists can improve patient care through metabolic syndrome monitoring and recommendation of appropriate interventions. Monitoring for the metabolic adverse effects of antipsychotics, management of weight gain, and management of lipids and blood pressure are explored through 2 patient cases.
Keyphrases
- metabolic syndrome
- weight gain
- cardiovascular disease
- blood pressure
- insulin resistance
- uric acid
- end stage renal disease
- cardiovascular risk factors
- body mass index
- randomized controlled trial
- chronic kidney disease
- ejection fraction
- newly diagnosed
- type diabetes
- physical activity
- birth weight
- prognostic factors
- heart rate
- emergency department
- primary care
- case report
- weight loss
- skeletal muscle
- adipose tissue
- drug induced
- preterm birth
- hypertensive patients
- general practice
- blood glucose
- high glucose
- adverse drug
- gestational age